|
1
|
Bellmunt J, de Wit R, Vaughn DJ, Fradet Y,
Lee JL, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK,
et al: Pembrolizumab as second-line therapy for advanced urothelial
carcinoma. N Engl J Med. 376:1015–1026. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Yarchoan M, Hopkins A and Jaffee EM: Tumor
Mutational Burden and response rate to PD-1 inhibition. N Engl J
Med. 377:2500–2501. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rosenberg JE, Hoffman-Censits J, Powles T,
van der Heijden MS, Balar AV, Necchi A, Dawson N, O'Donnell PH,
Balmanoukian A, Loriot Y, et al: Atezolizumab in patients with
locally advanced and metastatic urothelial carcinoma who have
progressed following treatment with platinum-based chemotherapy: A
single-arm, multicentre, phase 2 trial. Lancet. 387:1909–1920.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bagley SJ, Kothari S, Aggarwal C, Bauml
JM, Alley EW, Evans TL, Kosteva JA, Ciunci CA, Gabriel PE, Thompson
JC, et al: Pretreatment neutrophil-to-lymphocyte ratio as a marker
of outcomes in nivolumab-treated patients with advanced
non-small-cell lung cancer. Lung Cancer. 106:1–7. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Riedl JM, Barth DA, Brueckl WM, Zeitler G,
Foris V, Mollnar S, Stotz M, Rossmann CH, Terbuch A, Balic M, et
al: C-reactive protein (CRP) levels in immune checkpoint inhibitor
response and progression in advanced non-small cell lung cancer: A
Bi-center study. Cancers (Basel). 12:23192020. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Weide B, Martens A, Hassel JC, Berking C,
Postow MA, Bisschop K, Simeone E, Mangana J, Schilling B, Di
Giacomo AM, et al: Baseline biomarkers for outcome of melanoma
patients treated with pembrolizumab. Clin Cancer Res. 22:5487–5496.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kagamu H, Kitano S, Yamaguchi O, Yoshimura
K, Horimoto K, Kitazawa M, Fukui K, Shiono A, Mouri A, Nishihara F,
et al: CD4+ T-cell immunity in the peripheral blood
correlates with response to anti-PD-1 therapy. Cancer Immunol Res.
8:334–344. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Mazzaschi G, Facchinetti F, Missale G,
Canetti D, Madeddu D, Zecca A, Veneziani M, Gelsomino F, Goldoni M,
Buti S, et al: The circulating pool of functionally competent NK
and CD8+ cells predicts the outcome of anti-PD1 treatment in
advanced NSCLC. Lung Cancer. 127:153–163. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ornstein MC, Diaz-Montero CM, Rayman P,
Elson P, Haywood S, Finke JH, Kim JS, Pavicic PG Jr, Lamenza M,
Devonshire S, et al: Myeloid-derived suppressors cells (MDSC)
correlate with clinicopathologic factors and pathologic complete
response (pCR) in patients with urothelial carcinoma (UC)
undergoing cystectomy. Urol Oncol. 36:405–412. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Jones BR, Miller RL, Kinloch NN, Tsai O,
Rigsby H, Sudderuddin H, Shahid A, Ganase B, Brumme CJ, Harris M,
et al: Genetic diversity, compartmentalization, and age of HIV
proviruses persisting in CD4+ T cell subsets during
long-term combination antiretroviral therapy. J Virol.
94:e01786–19. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bronte V, Brandau S, Chen SH, Colombo MP,
Frey AB, Greten TF, Mandruzzato S, Murray PJ, Ochoa A,
Ostrand-Rosenberg S, et al: Recommendations for myeloid-derived
suppressor cell nomenclature and characterization standards. Nat
Commun. 7:121502016. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Miyara M, Yoshioka Y, Kitoh A, Shima T,
Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, et al:
Functional delineation and differentiation dynamics of human
CD4+ T cells expressing the FoxP3 transcription factor.
Immunity. 30:899–911. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Subramanian A, Kuehn H, Gould J, Tamayo P
and Mesirov JP: GSEA-P: A desktop application for gene set
enrichment analysis. Bioinformatics. 23:3251–3253. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Angelova M, Charoentong P, Hackl H,
Fischer ML, Snajder R, Krogsdam AM, Waldner MJ, Bindea G, Mlecnik
B, Galon J and Trajanoski Z: Characterization of the
immunophenotypes and antigenomes of colorectal cancers reveals
distinct tumor escape mechanisms and novel targets for
immunotherapy. Genome Biol. 16:642015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Cassetta L, Fragkogianni S, Sims AH,
Swierczak A, Forrester LM, Zhang H, Soong DYH, Cotechini T, Anur P,
Lin EY, et al: Human tumor-associated macrophage and monocyte
transcriptional landscapes reveal cancer-specific reprogramming,
biomarkers, and therapeutic targets. Cancer Cell. 35:588–602.e10.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zelba H, Bochem J, Pawelec G, Garbe C,
Wistuba-Hamprecht K and Weide B: Accurate quantification of T-cells
expressing PD-1 in patients on anti-PD-1 immunotherapy. Cancer
Immunol Immunother. 67:1845–1851. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Mariathasan S, Turley SJ, Nickles D,
Castiglioni A, Yuen K, Wang Y, Kadel EE III, Koeppen H, Astarita
JL, Cubas R, et al: TGFβ attenuates tumour response to PD-L1
blockade by contributing to exclusion of T cells. Nature.
554:544–548. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wei SC, Levine JH, Cogdill AP, Zhao Y,
Anang NAS, Andrews MC, Sharma P, Wang J, Wargo JA, Pe'Er D and
Allison JP: Distinct cellular mechanisms underlie anti-CTLA-4 and
anti-PD-1 checkpoint blockade. Cell. 170:1120–1133.e17. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Shyer JA, Flavell RA and Bailis W:
Metabolic signaling in T cells. Cell Res. 30:649–659. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Janelle V, Neault M, Lebel MÈ, De Sousa
DM, Boulet S, Durrieu L, Carli C, Muzac C, Lemieux S, Labrecque N,
et al: p16INK4a regulates cellular senescence in
PD-1-expressing human T cells. Front Immunol. 12:6985652021.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ruhland MK and Alspach E: Senescence and
immunoregulation in the tumor microenvironment. Front Cell Dev
Biol. 9:7540692021. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Francisco LM, Salinas VH, Brown KE,
Vanguri VK, Freeman GJ, Kuchroo VK and Sharpe AH: PD-L1 regulates
the development, maintenance, and function of induced regulatory T
cells. J Exp Med. 206:3015–3029. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Bagchi S, Yuan R and Engleman EG: Immune
checkpoint inhibitors for the treatment of cancer: Clinical impact
and mechanisms of response and resistance. Annu Rev Pathol.
16:223–249. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Limagne E, Richard C, Thibaudin M, Fumet
JD, Truntzer C, Lagrange A, Favier L, Coudert B and Ghiringhelli F:
Tim-3/galectin-9 pathway and mMDSC control primary and secondary
resistances to PD-1 blockade in lung cancer patients.
Oncoimmunology. 8:e15645052019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dumitru CA, Moses K, Trellakis S, Lang S
and Brandau S: Neutrophils and granulocytic myeloid-derived
suppressor cells: Immunophenotyping, cell biology and clinical
relevance in human oncology. Cancer Immunol Immunother.
61:1155–1167. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Hou A, Hou K, Huang Q, Lei Y and Chen W:
Targeting myeloid-derived suppressor cell, a promising strategy to
overcome resistance to immune checkpoint inhibitors. Front Immunol.
11:7832020. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vincent J, Mignot G, Chalmin F, Ladoire S,
Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and
Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated
myeloid-derived suppressor cells resulting in enhanced T
cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Z, Till B and Gao Q: Chemotherapeutic
agent-mediated elimination of myeloid-derived suppressor cells.
Oncoimmunology. 6:e13318072017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Li W, Zhang X, Chen Y, Xie Y, Liu J, Feng
Q, Wang Y, Yuan W and Ma J: G-CSF is a key modulator of MDSC and
could be a potential therapeutic target in colitis-associated
colorectal cancers. Protein Cell. 7:130–140. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Highfill SL, Cui Y, Giles AJ, Smith JP,
Zhang H, Morse E, Kaplan RN and Mackall CL: Disruption of
CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Sci Transl Med. 6:237ra672014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li T, Liu T, Zhu W, Xie S, Zhao Z, Feng B,
Guo H and Yang R: Targeting MDSC for immune-checkpoint blockade in
cancer immunotherapy: Current progress and new prospects. Clin Med
Insights Oncol. Aug 5–2021.(Epub ahead of print). View Article : Google Scholar
|
|
32
|
Younis RH, Han KL and Webb TJ: Human head
and neck squamous cell carcinoma-associated semaphorin 4D induces
expansion of myeloid-derived suppressor cells. J Immunol.
196:1419–1429. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Younis RH, Ghita I, Elnaggar M,
Chaisuparat R, Theofilou VI, Dyalram D, Ord RA, Davila E, Tallon
LJ, Papadimitriou JC, et al: Soluble Sema4D in plasma of head and
neck squamous cell carcinoma patients is associated with underlying
non-inflamed tumor profile. Front Immunol. 12:5966462021.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Clavijo PE, Friedman J, Robbins Y, Moore
EC, Smith E, Zauderer M, Evans EE and Allen CT: Semaphorin4D
inhibition improves response to immune-checkpoint blockade via
attenuation of MDSC recruitment and function. Cancer Immunol Res.
7:282–291. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tzeng A, Diaz-Montero CM, Rayman PA, Kim
JS, Pavicic PG Jr, Finke JH, Barata PC, Lamenza M, Devonshire S,
Schach K, et al: Immunological correlates of response to immune
checkpoint inhibitors in metastatic urothelial carcinoma. Target
Oncol. 13:599–609. 2018. View Article : Google Scholar : PubMed/NCBI
|
